Hydroxyurea use in children with sickle cell disease
| Start HU treatment 15-20 mg/kg/d . | ||
|---|---|---|
| United States . | Europe . | Africa . |
| Consensus | No consensus | No consensus |
| After age 9 mo, regardless of clinical severity | Common selected indications: | After age 12 mo, regardless of clinical severity |
| • Recurrent VOC and/or ACS | ||
| • After a period of transfusion and normalization of TCD in patients who have had an abnormal TCD finding | ||
| • Baseline Hb level <7 g/dL | ||
| • Renal impairment | ||
| • Chronic hypoxemia | ||
| • Cerebral silent infarct | ||
| • Conditional velocities on TCD | ||
| Start HU treatment 15-20 mg/kg/d . | ||
|---|---|---|
| United States . | Europe . | Africa . |
| Consensus | No consensus | No consensus |
| After age 9 mo, regardless of clinical severity | Common selected indications: | After age 12 mo, regardless of clinical severity |
| • Recurrent VOC and/or ACS | ||
| • After a period of transfusion and normalization of TCD in patients who have had an abnormal TCD finding | ||
| • Baseline Hb level <7 g/dL | ||
| • Renal impairment | ||
| • Chronic hypoxemia | ||
| • Cerebral silent infarct | ||
| • Conditional velocities on TCD | ||
ACS, acute chest syndrome; Hb, hemoglobin; HU, hydroxyurea; TCD, transcranial Doppler ultrasonography; VOC, vaso-occlusive crisis.